Glancy Prongay & Murray LLP Commences Investigation on Behalf of Sorrento Therapeutics, Inc. Investors (SRNE)

LOS ANGELES

Mar. 14, 2018 5:48 pm


Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) investors concerning the Company and its directors’ and officers’ possible violations of state laws.

If you purchased Sorrento Therapeutics stock, have information, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at 888-773-9244, or Bryan Faubus, of GPM, 230 Park Avenue, Suite 530, New York, NY 10169 at 212-682-5340 or at bfaubus@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP
Lesley Portnoy, 310-201-9150 or 888-773-9224
Bryan Faubus, 212-682-5340
bfaubus@glancylaw.com
www.glancylaw.com

Business Wire
March 14, 2018 - 5:48 PM EDT


"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market